Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, +15

New England Journal of Medicine

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, +20

New England Journal of Medicine

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations

Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, +15

Journal of Clinical Oncology

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler, +23

The Lancet Oncology

Lux-lung 3Lux-lung 6MedicinePathologyBronchial Neoplasm +7

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Martin Reck, Joachim von Pawel, Petr Zatloukal, +8

Journal of Clinical Oncology

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

David H. Henry, Luís Costa, François Goldwasser, +15

Journal of Clinical Oncology

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Edward S. Kim, Vera Hirsh, Tony Mok, +15

The Lancet

Non-small-cell Lung CancerMedicineMetronomic TherapyClinical TrialsBronchial Neoplasm +7

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne, +20

The Lancet Oncology

OncologyPhase 2BPathologyBronchial NeoplasmAfatinib Versus Gefitinib +6

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Vincent A. Miller, Vera Hirsh, Jacques Cadranel, +15

The Lancet Oncology

OncologyPhase 2B/3Afatinib Versus PlaceboClinical TrialsLux-lung 1 +7

Weekly <i>nab</i>-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

Mark A. Socinski, Igor Bondarenko, Nina Karaseva, +8

Journal of Clinical Oncology